NHWD 870
Alternative Names: NHWD-870Latest Information Update: 05 Aug 2024
At a glance
- Originator Ningbo Wenda Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors; Mitogen-activated protein kinase inhibitors; Platelet-derived growth factor beta receptor modulators; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-myc inhibitors; Proto-oncogene protein inhibitors; STAT1 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Squamous cell cancer
- Phase I Non-Hodgkin's lymphoma
Most Recent Events
- 05 Aug 2024 Phase-I clinical trials in Non-Hodgkin's lymphoma (PO), prior to August 2024 (Wenda pharma pipeline, August 2024)
- 05 Aug 2024 Ningbo Wenda Pharma announces intention to submit NDA to regulatory body for Squamous cell cancer in 2025 (Ningbo Wenda Pharma pipeline, August 2024)
- 25 Apr 2024 Phase-II clinical trials in Squamous cell cancer (Late-stage disease, In adolescents, In adults, In the elderly) in China (PO) (NCT06527300)